Short answer
FENNEC PHARMACEUTICALS INC. (FENC) filed an 8-K current report with the SEC on March 4, 2026 reporting Item 8.01 (Other Events). Tampa General Hospital Cancer Institute initiating real-world study of PEDMARK® (sodium thiosulfate injection) in ototoxicity prevention.
FENNEC PHARMACEUTICALS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Tampa General Hospital Cancer Institute initiating real-world study of PEDMARK® (sodium thiosulfate injection) in ototoxicity prevention
- Study expands PEDMARK® target population beyond current approved use: into adolescent, young adult, and adult cancer patients receiving cisplatin
- Positive real-world data could support label expansion, significantly broadening addressable market beyond current pediatric indication
- Investigator-initiated study signals growing clinical interest in PEDMARK® without direct R&D cost to Fennec
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other FENNEC PHARMACEUTICALS INC. 8-K filings
Get the next FENC 8-K as it lands
Follow FENC for push alerts, or ask the research agent what this filing means.